Taverne J, Delourme J, Dhalluin X, Copin M-C, Scherpereel A, Lafitte J-J, Cortot A B
Service de pneumologie et oncologie thoracique, hôpital Calmette, CHRU de Lille, boulevard du Pr-Leclercq, 59037 Lille, France.
Rev Pneumol Clin. 2013 Feb;69(1):36-40. doi: 10.1016/j.pneumo.2012.12.002. Epub 2013 Jan 18.
We report the case of a 55-year-old woman with pulmonary adenocarcinoma and bone metastases who was diagnosed with paraneoplastic secretion of the beta subunit of human chorionic gonadotropin (beta-HCG) while being screened for inclusion in a clinical trial. Immunohistochemistry analysis of a bone biopsy revealed strong staining of cancer cells with anti-beta HCG antibodies. Serial measurements of circulating Beta HCG seemed to be influenced by antineoplastic treatments, although they were not strictly associated with tumour evolution assessed by CT scans. Little is known about paraneoplastic secretion of beta HCG, although it has been found in 12% to 24% of non-small cell lung cancers. Usefulness of serial measurements of beta HCG for monitoring NSCLC has yet to be demonstrated, but its use as a criterion for inclusion in clinical trials needs to be questioned.
我们报告了一例55岁患有肺腺癌并伴有骨转移的女性病例，该患者在接受一项临床试验入选筛查时，被诊断为副肿瘤性分泌人绒毛膜促性腺激素β亚基（β-HCG）。对骨活检进行的免疫组织化学分析显示，癌细胞被抗β-HCG抗体强烈染色。尽管循环β-HCG的系列测量值似乎受到抗肿瘤治疗的影响，但它们与通过CT扫描评估的肿瘤进展并无严格关联。虽然在12%至24%的非小细胞肺癌中发现了β-HCG的副肿瘤性分泌，但对此了解甚少。β-HCG系列测量用于监测非小细胞肺癌的有效性尚未得到证实，但其作为临床试验入选标准的用途值得质疑。
